KR100830268B1 - 단백질 합성 억제 유전자의 발현 증강제 - Google Patents
단백질 합성 억제 유전자의 발현 증강제 Download PDFInfo
- Publication number
- KR100830268B1 KR100830268B1 KR1020027008401A KR20027008401A KR100830268B1 KR 100830268 B1 KR100830268 B1 KR 100830268B1 KR 1020027008401 A KR1020027008401 A KR 1020027008401A KR 20027008401 A KR20027008401 A KR 20027008401A KR 100830268 B1 KR100830268 B1 KR 100830268B1
- Authority
- KR
- South Korea
- Prior art keywords
- ifn
- gene
- subtype
- expression
- protein synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000328539 | 2000-10-27 | ||
| JPJP-P-2000-00328539 | 2000-10-27 | ||
| JP2001116710A JP2002201141A (ja) | 2000-10-27 | 2001-04-16 | 蛋白質合成抑制遺伝子の発現増強剤 |
| JPJP-P-2001-00116710 | 2001-04-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20020065620A KR20020065620A (ko) | 2002-08-13 |
| KR100830268B1 true KR100830268B1 (ko) | 2008-05-16 |
Family
ID=26602905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027008401A Expired - Fee Related KR100830268B1 (ko) | 2000-10-27 | 2001-09-26 | 단백질 합성 억제 유전자의 발현 증강제 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6773701B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1329223A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002201141A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100830268B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2395324A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI283582B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002036153A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| JP4629964B2 (ja) * | 2003-09-12 | 2011-02-09 | 株式会社林原生物化学研究所 | ウシの消化器疾患治療剤 |
| CN101031655A (zh) | 2004-07-26 | 2007-09-05 | 陶氏环球技术公司 | 通过株工程改进蛋白表达的方法 |
| EP1867340A4 (en) | 2005-03-10 | 2009-12-23 | Hayashibara Biochem Lab | THERAPEUTIC AGENT FOR TREATING DISEASES IN THE BOVINE DIGESTIVE SYSTEM |
| JPWO2007037098A1 (ja) * | 2005-09-27 | 2009-04-02 | 株式会社林原生物化学研究所 | 繁殖障害改善剤 |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9394571B2 (en) | 2007-04-27 | 2016-07-19 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| CN104056254A (zh) * | 2013-03-18 | 2014-09-24 | 赛德医药科技股份有限公司 | 用以降低肝炎病患复发率的组合物 |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993016107A1 (en) | 1992-02-10 | 1993-08-19 | Interferon Sciences, Inc. | Improved alpha interferon composition and method for its production from human peripheral blood leukocytes |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5142199B2 (cg-RX-API-DMAC7.html) | 1972-09-04 | 1976-11-13 | ||
| GB2016015B (en) | 1978-01-22 | 1982-05-06 | Hayashibara Co | Method of preparing interferon and preparations containing interferon |
| JPS5639022A (en) | 1979-09-05 | 1981-04-14 | Hayashibara Biochem Lab Inc | Preparation of vaccine |
| JPS5654158A (en) | 1979-10-09 | 1981-05-14 | Hitachi Ltd | Control system for call waiting |
| JP2838800B2 (ja) | 1989-09-02 | 1998-12-16 | 株式会社林原生物化学研究所 | 減感作剤 |
| JP3232488B2 (ja) | 1992-08-20 | 2001-11-26 | 株式会社林原生物化学研究所 | プルラン高含有物とその製造方法並びに用途 |
| US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
| JPH07163368A (ja) | 1993-12-15 | 1995-06-27 | Hayashibara Biochem Lab Inc | 組換えdnaとその組換えdnaを含む形質転換体 |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| JP3467515B2 (ja) * | 1994-11-01 | 2003-11-17 | 財団法人ルイ・パストゥール医学研究センター | インターフェロン活性の測定法 |
| MY125300A (en) * | 1999-02-26 | 2006-07-31 | Inst Of Molecular And Cell Biology | Synergistic combination for treatment of viral-mediated diseases |
-
2001
- 2001-04-16 JP JP2001116710A patent/JP2002201141A/ja active Pending
- 2001-09-26 US US09/962,625 patent/US6773701B2/en not_active Expired - Fee Related
- 2001-09-26 CA CA002395324A patent/CA2395324A1/en not_active Abandoned
- 2001-09-26 KR KR1020027008401A patent/KR100830268B1/ko not_active Expired - Fee Related
- 2001-09-26 EP EP01972507A patent/EP1329223A4/en not_active Ceased
- 2001-09-26 WO PCT/JP2001/008390 patent/WO2002036153A1/ja not_active Ceased
- 2001-10-15 TW TW090125438A patent/TWI283582B/zh not_active IP Right Cessation
-
2004
- 2004-02-13 US US10/777,081 patent/US7189389B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993016107A1 (en) | 1992-02-10 | 1993-08-19 | Interferon Sciences, Inc. | Improved alpha interferon composition and method for its production from human peripheral blood leukocytes |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1329223A1 (en) | 2003-07-23 |
| US6773701B2 (en) | 2004-08-10 |
| US20040197307A1 (en) | 2004-10-07 |
| US7189389B2 (en) | 2007-03-13 |
| CA2395324A1 (en) | 2002-05-10 |
| KR20020065620A (ko) | 2002-08-13 |
| EP1329223A4 (en) | 2005-04-20 |
| JP2002201141A (ja) | 2002-07-16 |
| US20030039629A1 (en) | 2003-02-27 |
| TWI283582B (en) | 2007-07-11 |
| WO2002036153A1 (en) | 2002-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100223255B1 (ko) | 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법 | |
| US6060450A (en) | Method for treatment of autoimmune diseases | |
| TW542722B (en) | Orally-administered interferon-tau compositions | |
| Wang et al. | Cynoglossus semilaevis ISG15: a secreted cytokine-like protein that stimulates antiviral immune response in a LRGG motif-dependent manner | |
| KR100496460B1 (ko) | 폴리펩티드 | |
| US7655628B2 (en) | Method for treating liver cirrhosis or interstitial pulmonary fibrosis | |
| CN103483443A (zh) | 重组人干扰素样蛋白 | |
| Masci et al. | New and modified interferon alfas: preclinical and clinical data | |
| US6773701B2 (en) | Expression enhancer for protein synthesis inhibitory genes | |
| Taylor | Interferons | |
| JP2003327542A (ja) | インターフェロン−γの産生を誘導するポリペプチド | |
| EP1326628B1 (en) | Chemokine mutants in the treatment of multiple sclerosis | |
| Ooi et al. | Biological characterisation of a recombinant Atlantic salmon type I interferon synthesized in Escherichia coli | |
| AU2002215919A1 (en) | Chemokine mutants in the treatment of multiple sclerosis | |
| CZ20024094A3 (cs) | Farmaceutický přípravek pro léčení sclerosis multiplex obsahující nový interferon | |
| Kim et al. | Species specific antiviral activity of porcine interferon-α8 (IFNα8) | |
| Schein et al. | Deletions at the C-terminus of interferon γ reduce RNA binding and activation of double-stranded-RNA cleavage by bovine seminal ribonuclease | |
| KASHIMA et al. | Expression of bovine cytokines in Escherichia coli | |
| Broeze et al. | Studies with Pure Mouse Ehrlich Ascites Tumor Interferons α and β: Patterns of Induction of (2′-5′)(A) n Synthetase and of a Double-Stranded RNA-Dependent Protein Kinase in Mouse Cells and Human Cells | |
| Aboagye‐Mathiesen et al. | Interferon gamma regulates a unique set of proteins in fresh human bladder transitional cell carcinomas | |
| Watanabe et al. | Interleukin-22 induces immune-related gene expression in the gills of Japanese medaka Oryzias latipes | |
| Hayes | Differences between human α (leukocyte) and β (fibroblast) interferons | |
| CN111825773B (zh) | 重组人TSG6-IFNα融合蛋白及其制备方法以及其作为抗病毒药物的应用 | |
| Kang et al. | Amino acid differences in interferon-tau (IFN-τ) of Bos taurus Coreanae and Holstein | |
| RU2003334C1 (ru) | Способ лечени больных с опухол ми |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-5-5-R10-R17-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| FPAY | Annual fee payment |
Payment date: 20110428 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20120510 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20120510 |